On a relative basis, the stock has outperformed the S&P 500 by 5.34% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.81% in the last 1 week, and is up 9.94% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 4.43% and the 50-Day Moving Average is 1.64%.
Opko Health Inc (NYSE:OPK): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $9.82 and $9.76 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $9.98. The buying momentum continued till the end and the stock did not give up its gains. It closed at $9.95, notching a gain of 1.02% for the day. The total traded volume was 1,648,107 . The stock had closed at $9.85 on the previous day.
The company Insiders own 40.74% of Opko Health Inc shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -11.66% . Institutional Investors own 19.77% of Opko Health Inc shares. During last six month period, the net percent change held by insiders has seen a change of -0.09%. In a related news, Frost Gamma Investments Trust, CEO of Opko Health, Inc., executed a transaction worth $152,628 on July 13, 2016. A total of 15,800 shares were purchased at an average price of $9.66. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.